This paper is a brief review of silver complexes that have been identified as antibacterial drugs with promising use for the treatment of tuberculosis (TB). This treatment aims to cure and discontinue the transmission of the disease. The excessive and inappropriate use of drugs has jeopardized the effectiveness of antibiotics for the TB treatment, bringing bacterial resistance to them. To achieve these objectives, the drugs used must be able to eliminate rapidly the bacterial population, avoiding the selection of drug-resistant strains and preventing its recurrence. The number of new cases of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) continues to rise. So, it is important to develop more research to introduce new drugs or improve existing ones, which can reduce the treatment time, increasing drug adherence and reducing MDR-TB and XDR-TB. The Ag(I) complexes were described with different types of ligands, and bonds to Ag(I) occur by N, O, P, and S atoms. Metal complexes are presented as options for anti-TB treatments. There are no cases of TB treatments using metal complexes but research in this area show that they could be used in the future to eradicate the bacteria that contaminate environments, surgical materials and other objects.

In the present work, a silver(I) complex with the antimycobacterial drug isoniazid (inh) is described. Elemental and thermogravimetric analyses confirmed a 1:1 metal:ligand ratio for the silver-isoniazid (Ag-inh) complex with molecular composition AgC6H7N3O·NO3. Infrared (IR) analysis suggests a bidentate coordination of isoniazid to silver by the nitrogen of the NH2 group and by the oxygen of the C=O group, and also confirms the presence of free nitrate anion. Coordination by the NH2 group was reinforced by NMR measurements. Computational simulations using the density functional theory (DFT) reinforced that the ligand coordinates to the silver atom by the NH2 and C=O groups. The silver complex presented a minimal inhibitory concentration (MIC90) of 0.78 µg/mL against the standard Mycobacterium tuberculosis strain H37Rv. The data reported herein warrants further investigation on Ag-inh complex as a potential agent against tuberculosis.

This article deals with synthesis and reactivity of complexes with triphenylstibine (SbPh3) as the ligand. A comparative study of analogous complexes of triphenylphosphine (PPh3) and triphenylarsine (AsPh3) with platinum in the oxidation states zero, two and four is included. The bibliographic revision includes publications since 1936, when the first Pt(II) complex with triphenylstibine was described.

This article describes the history of four decades of activities in the Institute of Chemistry of Araraquara, UNESP: the beginning, the evolution of undergraduate and graduate courses and the infra-structure of teaching and research.